Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyrophosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.35 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | INPP5B | P32019 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL145674 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL2325329 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL17765467 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL1985595 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL9522730 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL28049291 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL933099 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL3788496 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL23410734 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL11522910 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2014-06-19 | — | — | US | disclosed |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2111226-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | Normoxys, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | disclosed |
| WO-2008082658-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NORMOXYS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | PPIP5K2, IP6K1, IP6K3 | FDPS 249/4885BLM 4449/4885TDP1 3015/4885 |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | FDPS 144/4885BLM 4349/4885TDP1 2196/4885 |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | FDPS 144/4885BLM 4349/4885TDP1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.